



RELIEF THERAPEUTICS HOLDING SA

with seat in Geneva

INVITATION TO THE EXTRAORDINARY GENERAL MEETING

to be held on Friday, 14 November 2025, at 5:30 p.m. CET

(doors open at 5:00 p.m.)

at Avenue de Sécheron 15, 1202 Geneva, Switzerland

in accordance with Article 9 et seq. of the Articles of Association

Agenda

- 1. Ordinary Capital Increase**
- 2. Capital Band**
- 3. Conditional Capital**
- 4. Change of Company Name**
- 5. Amendment of Corporate Purpose**
- 6. Election of New Members of the Board of Directors and of the Chairman**
- 7. Election of New Members of the Nomination and Compensation Committee**

Invitation from the Board of Directors

Dear Shareholders,

The Board of Directors of RELIEF THERAPEUTICS Holding SA ("**Relief**" or the "**Company**") invites you to an Extraordinary General Meeting (the "**EGM**") to seek your approval for the proposed business combination between Relief and NeuroX Group SA, a digital therapeutics company domiciled in Lausanne, Canton of Vaud, and registered under no. CHE-324.977.766 ("**NeuroX**").

On October 8, 2025, we publicly announced that we had entered into a binding transaction agreement with NeuroX, which, subject to the fulfilment of the conditions set forth in the agreement, provides for a business combination between Relief and NeuroX (the "**Transaction**").

Under the terms of this agreement, Relief will acquire all outstanding shares of NeuroX from the existing NeuroX shareholders by way of a contribution in kind, in exchange for newly issued Relief shares. Upon Closing of the Transaction, NeuroX's shareholders will receive a total of 140 million Relief shares, and Relief will increase its share capital by a corresponding amount, from currently approximately 14 million outstanding shares. For the purposes of this invitation, the term "**Closing**" refers to the completion of the stock-for-stock exchange, pursuant to which the shareholders of NeuroX will contribute their shares to Relief in exchange for newly issued Relief shares.

The proposed business combination represents a compelling and risk-balanced growth opportunity. Earlier this year, NeuroX acquired strategic assets from MindMaze Group SA and MindMaze SA, establishing the foundation of its business. The Transaction will create a publicly listed, AI-based therapeutics platform integrating software-delivered, disease-modifying clinical interventions with pharmacological treatments and a comprehensive brain health platform. NeuroX contributes a clinically validated and de-risked portfolio, supported by milestones achieved across technological development, regulatory approvals, and market access, as well as a network of pharmaceutical partners. Together, the combined company will be uniquely positioned to advance precision neurology solutions and create sustainable value for shareholders.

The Transaction remains subject to certain closing conditions, including the approval by Relief's shareholders of all proposals to be voted on at this EGM, followed by the approval of SIX Swiss Exchange for the listing of the newly issued shares. We therefore invite all Relief shareholders to cast their votes in favor of all proposals, either by attending in person or by submitting a proxy vote.

We would like to take this opportunity to thank all Relief shareholders for their continued confidence and support.

With sincere thanks and best regards,

The Board of Directors
RELIEF THERAPEUTICS Holding SA

AGENDA, PROPOSALS AND EXPLANATIONS OF THE BOARD OF DIRECTORS

1 ORDINARY CAPITAL INCREASE

Motions

The Board of Directors proposes an ordinary capital increase as follows and the respective amendment of Article 3 (Share Capital) of the Company's Articles of Association:

- (a) the share capital of the Company shall be increased by up to CHF 14,000,000 by issuing up to 140,000,000 fully paid-up registered shares with a nominal value of CHF 0.10 each;
- (b) the issue price shall be CHF 0.10 per share and shall be paid in through contributions in kind of existing shares of NeuroX (1,000,000 registered shares with a nominal value of CHF 0.10 each);
- (c) the pre-emptive rights of existing Relief shareholders are excluded for good cause. The Board of Directors is authorized to allocate pre-emptive rights to some or all shareholders or to third parties, including third parties who have signed an agreement for the subscription and purchase of such shares to be issued;
- (d) the new Relief shares shall be entitled to dividends as from the date of their issuance and shall be subject to the restrictions on transferability in accordance with Article 5 of the Articles of Association.

The resolution under this agenda item is conditional upon the EGM approving the proposals of the Board of Directors under agenda items 4, 5 and 6.

Explanations

For the purpose of effecting the proposed business combination with NeuroX, the Board of Directors proposes to increase the Company's share capital in order that shareholders of NeuroX receive newly issued shares of the Company in consideration of and by contributing their respective shares of NeuroX to the Company by way of contribution in kind, at a fixed exchange ratio of 140 Relief shares for each NeuroX share. Upon completion of the ordinary capital increase, NeuroX's shareholders are expected to own approximately 91.75% and Relief's existing shareholders approximately 8.25% of Relief's issued and outstanding share capital.

This capital increase will be implemented and entered in the commercial register immediately prior to the Closing of the Transaction.

According to Swiss law and the Articles of Association, the proposed ordinary capital increase requires approval by two thirds of the votes and the majority of the nominal value of shares represented at the general meeting.

If the EGM approves the motion under this agenda item 1 but not the motions under agenda items 4, 5 and 6, the capital increase resolved under this agenda item 1 will not be valid.

2 CAPITAL BAND

Motions

The Board of Directors proposes (i) the introduction of a capital band from 100% of the share capital after implementation of the capital increase pursuant to agenda item 1 (lower limit) to approximately 126% of the share capital after implementation of the capital increase pursuant to agenda item 1 (upper limit), corresponding to 40,000,000 potential additional shares, as replacement of the existing capital band (Article 3a^{ter} of the current Articles of Association); the Board of Directors shall be authorized to increase the share capital within the capital band once or several times and in any amounts until November 13, 2030, or until an earlier expiry of the capital range and (ii) to delete and replace Article 3a^{ter} of the Articles of Association by a new Article 3a^{ter} as set out in the Annex with effect as of the completion of the ordinary capital increase according to agenda item 1.

The resolution under this agenda item is conditional upon the EGM approving the proposals of the Board of Directors under agenda items 1, 4, 5 and 6.

Explanations

Generally, a capital band may authorize the Board of Directors of a company to increase or reduce the share capital within a certain range of the share capital registered in the commercial register at the time the capital band is introduced. The authorization is limited by law to five years. The general meeting of shareholders has the right to restrict or cancel the subscription rights of the shareholders directly, or it may delegate this right to the Board of Directors, provided that the reasons for the restriction or cancellation of the subscription rights are specified in the Articles of Association.

The capital band provides the Board of Directors with a flexible instrument enabling it, among other things, to decrease the Company's share capital or to issue, without delay, new shares for financing purposes at a moment favorable to the Company.

The Board of Directors proposes to delete and replace the existing capital band in Article 3a^{ter} of the Company's Articles of Association with a new capital band in accordance with the Swiss corporate law. The Board of Directors proposes to introduce a capital band that enables the Board of Directors to increase or decrease the share capital of the Company by means of issuing or canceling new shares within the range of 100% to 126% of the share capital to be registered with the same commercial register application for a period of five years without an additional vote of the shareholders. The Board of Directors shall have the right to restrict or cancel shareholders' subscription rights in the event of an issue of shares within the capital band.

According to Swiss law, the resolution of the general meeting to introduce a capital range as proposed by the Board of Directors in this agenda item 2 requires approval by two thirds of the votes and the majority of the nominal value of shares represented at the general meeting.

If the EGM approves the motion under this agenda item 2 but not the motions under agenda items 1, 4, 5 and 6, the introduction of the capital band and the new Article 3a^{ter} of the Articles of Association proposed under this agenda item 2 cannot be validly resolved. The capital band and the new Article 3a^{ter} of the Articles of Association shall become effective upon the completion of the ordinary capital increase.

3 CONDITIONAL CAPITAL

Motions

The Board of Directors proposes (i) to increase the conditional capital pursuant to Article 3b^{bis} para. 1 of the Articles of Association to 15,000,000 Relief shares, (ii) to increase the conditional capital pursuant to Article 3b^{bis} para. 2 of the Articles of Association to 35,000,000 Relief shares, and (iii) to amend Article 3b^{bis} of the current Articles of Association as set out in the Annex with effect as of the completion of the ordinary capital increase according to agenda item 1.

The resolution under this agenda item is conditional upon the EGM approving the proposals of the Board of Directors under agenda items 1, 4, 5 and 6.

Explanations

Currently, the aggregate conditional capital under Article 3b^{bis} para. 1 and para. 2 of the Articles of Association amounts to CHF 700,000.00 allowing for the issuance of up to a total of 7,000,000 new Relief shares. In this agenda item 3, the Board of Directors proposes increasing the existing conditional capital. Such conditional capital would be used, as the existing conditional capital, for existing or new share delivery obligations of the Company, which otherwise have to be covered by shares from other sources. If approved, the new conditional capital in the aggregate amount of CHF 5,000,000.00, allowing for the issuance of up to a total of 50,000,000 new RLF shares according to Article 3b^{bis} para. 1 and para. 2 would correspond to around 32.5% of the Company's share capital in total, to be registered with the same commercial register application.

The new conditional capital under Article 3b^{bis} para. 1 would be used to source the shares required under certain employee participation plans. The new conditional capital under Article 3b^{bis} para. 2 would be used to source the shares required for outstanding warrants as well as for potential future equity-linked financing transactions executed to fund the Company post the Transaction providing a right to receive shares of the Company.

As of the date of this invitation, the Company has issued 51'480 shares out of its existing conditional capital, which have not yet been registered as ordinary share capital. Such shares will be registered as ordinary share capital from the conditional capital after the Closing of the Transaction.

According to Swiss law, the resolution of the general meeting to increase the conditional capital as proposed by the Board of Directors in this agenda item 3 requires approval by two thirds of the votes and the majority of the nominal value of shares represented at the general meeting.

If the EGM approves the motion under this agenda item 3 but not the motions under agenda items 1, 4, 5 and 6, the introduction of the new conditional capital and the new Article 3b^{bis} of the Articles of Association proposed under this agenda item 3 cannot be validly resolved. The new conditional capital and the new Article 3b^{bis} of the Articles of Association shall become effective upon the completion of the ordinary capital increase.

4 CHANGE OF COMPANY NAME

Motions

The Board of Directors proposes that the Company's name be changed from RELIEF THERAPEUTICS Holding SA to MindMaze Therapeutics Holding SA (MindMaze Therapeutics Holding Ltd) (MindMaze Therapeutics Holding AG) and accordingly that Article 1 of the Articles of Association be revised as set out in the Annex with effect as of the completion of the ordinary capital increase according to agenda item 1.

The resolution under this agenda item is conditional upon the EGM approving the proposals of the Board of Directors under agenda items 1, 5 and 6.

Explanations

The Board of Directors would like to reflect the proposed business combination transaction in the Company's corporate name. The Board of Directors therefore proposes changing the corporate name of the Company from RELIEF THERAPEUTICS Holding SA to MindMaze Therapeutics Holding SA and to amend Article 1 of the Articles of Association accordingly as set out in the Annex.

According to Swiss law, the resolution of the general meeting to change the Company's corporate name as proposed by the Board of Directors in this agenda item 4 requires approval by the majority of the votes represented at the general meeting.

If the EGM approves the motion under this agenda item 4 but not the motions under agenda items 1, 5 and 6, the change of the corporate name proposed under this agenda item 4 cannot be validly resolved.

5 AMENDMENT OF CORPORATE PURPOSE

Motions

The Board of Directors proposes to change the corporate purpose of the Company and to amend Article 2 of the Articles of Association as set out in the Annex with effect as of the completion of the ordinary capital increase according to agenda item 1.

The resolution under this agenda item is conditional upon the EGM approving the proposals under agenda items 1, 4, and 6.

Explanations

The Board of Directors would like to reflect the proposed business combination transaction, and particularly NeuroX's business activities, in the Company's corporate purpose. For this purpose, the Board of Directors proposes to amend Article 2 of the Articles of Association as set out in the Annex.

According to Swiss law, the resolution of the general meeting to change the Company's purpose as proposed by the Board of Directors under this agenda item 5 requires approval by two thirds of the votes and the majority of the nominal value of shares represented at the general meeting.

If the EGM approves the motion under this agenda item 5 but not the motions under agenda items 1, 4 and 6, the change of purpose proposed under this agenda item 5 cannot be validly resolved.

6 ELECTION OF NEW MEMBERS OF THE BOARD OF DIRECTORS AND OF THE CHAIRMAN

Motions

(6.1) Election of Mr. Walid Hanna

The Board of Directors proposes the election of Mr. Walid Hanna as a member and Chairman of the Board of Directors until the end of the 2026 annual general meeting.

(6.2) Election of Mr. Olaf Blanke

The Board of Directors proposes the election of Mr. Olaf Blanke as a member of the Board of Directors until the end of the 2026 annual general meeting.

(6.3) Election of Mr. Michael Stuenkel

The Board of Directors proposes the election of Mr. Michael Stuenkel as a member of the Board of Directors until the end of the 2026 annual general meeting.

(6.4) Election of Mr. Martin Reiss

The Board of Directors proposes the election of Mr. Martin Reiss as a member of the Board of Directors until the end of the 2026 annual general meeting.

The resolutions under these agenda items are conditional upon the EGM approving the proposals under agenda items 1, 4, and 5.

The newly elected members of the Board of Directors will take office contingent upon and effective as of the Closing of the Transaction.

Explanations

The members and the Chairman of the Board of Directors shall be elected individually. The term of office of all members of the Board of Directors will start at the Closing of the Transaction and end at next year's annual general meeting. Dr. Raghuram Selvaraju, Mr. Peter de Svastich and Mr. Thomas Elzinga have decided to resign from the Board of Directors, contingent upon and effective as of Closing of the Transaction. Incumbent director Mr. Gregory Van Beek will remain on the Board of Directors.

Walid Hanna is the Chairman and Chief Executive Officer of Perseus Biomics, a company focused on microbiome mapping for precision medicine. He has over 25 years of experience in the healthcare sector, including senior leadership roles at Cardinal Health, where he served as Senior Vice President, and at Medtronic, where he was responsible for global strategy, mergers and acquisitions, and business development. Mr. Hanna also founded MedVent Group, an investment and advisory firm supporting healthcare ventures.

Olaf Blanke holds the Bertarelli Foundation Chair in Cognitive Neuroprosthetics at the École Polytechnique Fédérale de Lausanne (EPFL) and serves as Professor of Neurology at the University of Geneva and Geneva University Hospitals. At EPFL, he founded the Laboratory of Cognitive Neuroscience and the Center for Neuroprosthetics. His research bridges cognitive neuroscience, neuroengineering, robotics, and virtual reality to develop new solutions for brain and body disorders. Professor Blanke is internationally recognized for pioneering research on self-consciousness, embodiment, and the integration of neuroscience with technology and received numerous scientific honors, including the Cloëtta Prize, Robert Bing Prize, Pfizer Research Prize, and Leenaards Prize.

Michael Stuenkel is the Founder and Chief Executive Officer of Bayhouse Capital, an investment firm based in Hong Kong focused on high-growth opportunities. He has over 15 years of experience in global finance and venture capital. Prior to founding Bayhouse Capital, Mr. Stuenkel was a Founding Partner at Lakestar, where he contributed to establishing the firm's European venture capital platform in Zurich and Hong Kong. Earlier in his career, he founded and led Trayas Investments in Switzerland and began his professional career as an Analyst at UBS Investment Bank in London.

Martin Reiss has over 40 years of experience in sports marketing and communications. He founded a Zurich-based agency and has advised global companies including Philip Morris, Nestlé, Mercedes, Audi, and UBS. Mr. Reiss has developed commercial partnerships in Formula One and currently oversees business development at McLaren Technology Group while leading Allsport-Promotion, a sports marketing agency. He has also managed sports personalities in Formula One, tennis, and skiing, and organized major events such as the Kremlin Cup in Moscow and the Bobsleigh World Cup in St. Moritz.

If the EGM approves the motions under these agenda items 6.1 to 6.4 but not the motions under agenda items 1, 4, and 5, the candidates cannot be validly elected to the Board of Directors.

7 ELECTION OF NEW MEMBERS OF THE NOMINATION AND COMPENSATION COMMITTEE

Motions

(7.1) Election of Mr. Walid Hanna

The Board of Directors proposes the election of Mr. Walid Hanna as a member of the Nomination and Compensation Committee until the end of next year's annual general meeting.

(7.2) Election of Mr. Martin Reiss

The Board of Directors proposes the election of Mr. Martin Reiss as a member of the Nomination and Compensation Committee until the end of next year's annual general meeting.

(7.3) Election of Mr. Gregory Van Beek

The Board of Directors proposes the election of Mr. Gregory Van Beek as a member of the Nomination and Compensation Committee until the end of next year's annual general meeting.

The resolutions under this agenda item 7 are conditional upon the EGM approving the proposals of the Board of Directors under agenda items 1, 4, 5 and 6.

Explanations

The members of the Compensation Committee shall be elected individually and will have to be elected again by the 2026 annual general meeting. Only members of the Board of Directors are eligible.

If the EGM approves the motions under these agenda items 7.1 to 7.3 but not the motions under agenda items 1, 4, 5 and 6, the candidates cannot be validly elected to the Compensation Committee.

Organizational Notes

Entitlement to vote. Shareholders registered in the share register as of 29 October 2025 at 05:00 p.m. CEST are entitled to vote. No registration in the share register will be made from that date through the General Meeting date. Shareholders who sell all or part of their shares prior to the General Meeting will no longer be entitled to vote to that extent.

Admission Tickets. The General Meeting will be held in person at Avenue de Sécheron 15, 1202 Geneva. Shareholders shall confirm their attendance by returning the enclosed registration form by mail, or by ordering their admission ticket through the Investor Portal, no later than 7 November 2025. Admission tickets will be sent by 10 November 2025 to shareholders who registered for the General Meeting.

Proxy Appointment. A shareholder may only be represented at the General Meeting of shareholders by their legal representative, who does not have to be a shareholder, or by means of a written or electronic proxy, or another shareholder with voting rights, or the independent proxy (by way of a written or electronic proxy). All shares held by a shareholder must be represented by a single representative. The Company shall only accept one representative per share.

Independent Proxy. The shareholders may give voting instructions to the independent proxy, Mr. Thomas Hua, esq., partner at gbf Avocats SA, route de Pré-Bois 20, 1215 Genève Aéroport, Switzerland, and exercise certain other shareholder rights through him. This may be done in writing, by mail or electronically. For the electronic instructions to the independent representative, the necessary information and login details can be found in the enclosure. Instructions transmitted electronically should be executed no later than 12 November 2025, 11.59 p.m. CEST.

Web portal "Investor Portal". The Company offers its shareholders the use of the "Investor Portal" shareholder platform to order their admission ticket, appoint a proxy and give voting instructions. Shareholders registered in the Company's share register receive the login codes with the invitation to the General Meeting. If you have questions, please contact Computershare Switzerland Ltd, operator of the online portal, by email at business.support@computershare.ch or by phone at +41 62 205 77 50 (08:00 a.m. to 05:00 p.m. CEST).

Proposals from Shareholders on Agenda Items. Proposals from shareholders on agenda items are only permissible if they are put to the General Meeting by the shareholders themselves or by an individual proxy acting on their behalf. The independent proxy cannot act as an individual proxy in this sense.

Annexes:

Amendments to the Articles of Association

Registration form / Proxy with return envelope

Instruction form

ANNEX – AMENDMENTS TO THE ARTICLES OF ASSOCIATION

Current Article	New Article
Article 1 Company Name, Registered Seat and Duration	Article 1 Company Name, Registered Seat and Duration
1 Under the name RELIEF THERAPEUTICS Holding SA (RELIEF THERAPEUTICS Holding LTD) (RELIEF THERAPEUTICS Holding AG) there exists a share corporation as defined in title 26 of the Swiss Code of Obligations (CO) and in these Articles of Association with its registered office in Geneva, canton of Geneva (the "Company"). 2 The duration of the Company is unlimited.	1 Under the name MindMaze Therapeutics Holding SA (MindMaze Therapeutics Holding Ltd) (MindMaze Therapeutics Holding AG) there exists a share corporation as defined in title 26 of the Swiss Code of Obligations (CO) and in these Articles of Association with its registered office in Geneva, canton of Geneva (the "Company"). 2 The duration of the Company is unlimited.
Article 2 Purpose	Article 2 Purpose
1 The purpose of the Company is to research, develop, produce and sell products in the fields of biotechnology, pharmaceutical, diagnosis, therapy as well as to purchase, sell and use patents and licenses in this field. The Company may engage in all types of transactions that appear appropriate to promote the purpose of the Company or that are related thereto, including the acquisition, the holding, the management, the sale and the financing of direct and indirect participations in enterprises of all kind in Switzerland or abroad, in particular in the field of rendering preclinical, clinical and regulatory services and in the economic and scientific development of new therapeutic concepts and solutions for the treatment of diseases, medical indications and therapeutic treatments. 2 In addition, the Company may engage in any other commercial, financial or other activities, which are suitable to favour the purpose of the Company or which are directly or indirectly related to the purpose of the Company. Particularly, the Company may grant loans, guarantees and other kinds of financing and securing for companies of the group. [Deleted] 3 The Company may establish branches and subsidiaries within Switzerland or abroad and may acquire participations in other companies and manage, exploit and sell real estate and intellectual property rights in Switzerland or abroad.	1 The purpose of the Company is to research, develop, produce and sell products in the fields of biotechnology, pharmaceutical, diagnosis, therapy, chemical, and cosmetical products, as well as to purchase, sell and use patents and licenses in this field. The Company may engage in all types of transactions that appear appropriate to promote the purpose of the Company or that are related thereto, including the acquisition, the holding, the management, the sale and the financing of direct and indirect participations in enterprises of all kind in Switzerland or abroad, in particular in the field of rendering preclinical, clinical and regulatory services in companies that undertake research and development, manufacture, trade and distribute pharmaceutical, chemical and cosmetical products of all kinds and in the economic and scientific development of new therapeutic concepts and solutions for the treatment of diseases, medical indications and therapeutic treatments. 2 The Company may establish branches and subsidiaries within Switzerland or abroad and may acquire participations in other companies and manage, exploit and sell real estate. The Company may acquire, hold and sell trademarks, copyrights, designs and other intellectual property rights in Switzerland or abroad. 3 The Company may provide and/or obtain financings of any kind for its own account or for the account of another party and in particular enter into loan or security transactions with or without consideration, with or on behalf of any direct or indirect subsidiary and other affiliated companies. The Company may also provide management services for parent, subsidiary or other affiliated companies. 4 The Company may do all business and take all measures which are deemed appropriate in furthering the purpose of the Company or which are directly or indirectly connected with its purpose.

Article 3 Share Capital	Article 3 Share Capital
The share capital of the Company amounts to CHF 1'404'083.70, divided into 14'040'837 registered shares with a par value of CHF 0.10 each. The shares are fully paid up.	The share capital of the Company amounts to CHF 15'404'083.70, divided into 154'040'837 registered shares with a par value of CHF 0.10 each. The shares are fully paid up.
Article 3a^{ter} Capital Band	Article 3a^{ter} Capital Band
1 The Board of Directors shall be authorized, at any time until 25 April 2029, to increase the share capital at any time and as often as desired within the lower limit of CHF 1'404'083.70 and the upper limit of CHF 2'104'083.70 by issuance of up to 7'000'000 fully paid in registered shares with a nominal value of CHF 0.10 each (capital band). A capital reduction shall be excluded. An increase in partial amounts is permitted. Furthermore, within the limits of Article 659 and ss. of the Swiss Code of Obligations, an increase by original subscription of shares by the Company for the purpose of subsequent offers to shareholders or third parties or distribution among them is permitted. The Board of Directors will determine the appropriate issue price, the date of dividend entitlement and the way of contribution. The Board of Directors may issue new shares by means of underwriting or in any other manner by one or more banks and subsequent offer to shareholders or third parties. The Board of Directors is authorized to permit, to restrict or to deny the trade of subscription rights. The Board of Directors may forfeit unexercised subscription rights, or it can distribute these or the shares for which subscription rights have been granted but not exercised at market conditions or otherwise use them in the interest of the Company. 2 [Unchanged] 3 [Unchanged] 4 [Unchanged]	1 The Board of Directors shall be authorized, at any time until 13 November 2030, to increase the share capital at any time and as often as desired within the lower limit of CHF 15'404'083.70, and the upper limit of CHF 19'404'083.70, by issuance of up to 40'000'000 fully paid in registered shares with a nominal value of CHF 0.10 each (capital band). A capital reduction shall be excluded. An increase in partial amounts is permitted. Furthermore, within the limits of Article 659 and ss. of the Swiss Code of Obligations, an increase by original subscription of shares by the Company for the purpose of subsequent offers to shareholders or third parties or distribution among them is permitted. The Board of Directors will determine the appropriate issue price, the date of dividend entitlement and the way of contribution. The Board of Directors may issue new shares by means of underwriting or in any other manner by one or more banks and subsequent offer to shareholders or third parties. The Board of Directors is authorized to permit, to restrict or to deny the trade of subscription rights. The Board of Directors may forfeit unexercised subscription rights, or it can distribute these or the shares for which subscription rights have been granted but not exercised at market conditions or otherwise use them in the interest of the Company. 2 [Unchanged] 3 [Unchanged] 4 [Unchanged]
Article 3b^{bis} Conditional Share Capital	Article 3b^{bis} Conditional Share Capital
1 The share capital of the Company may be increased by the issuance of up to 1'000'000 registered shares to be fully paid up, each with a par value of CHF 0.10 to the nominal value of CHF 100'000.00 through the exercise of options granted to employees, members of the Board of Directors and consultants of the Company or its subsidiaries. The subscription rights and preemptive rights of the shareholders of the Company are excluded in connection with the issuance of any shares, options or subscription rights thereof. The option rights for employees, members of the Board of Directors and consultants are issued by the Company. The terms of the options, such as the issue price of the shares, date of dividend entitlement and way of contribution are determined by the Board of Directors in the context of regulations. The exercise of the option rights and the waiver of such right shall be made in writing on paper or in electronic form.	1 The share capital of the Company may be increased by the issuance of up to 15'000'000 registered shares to be fully paid up, each with a par value of CHF 0.10 to the nominal value of CHF 1'500'000.00 through the exercise of options granted to employees, members of the Board of Directors and consultants of the Company or its subsidiaries. The subscription rights and preemptive rights of the shareholders of the Company are excluded in connection with the issuance of any shares, options or subscription rights thereof. The option rights for employees, members of the Board of Directors and consultants are issued by the Company. The terms of the options, such as the issue price of the shares, date of dividend entitlement and way of contribution are determined by the Board of Directors in the context of regulations. The exercise of the option rights and the waiver of such right shall be made in writing on paper or in electronic form.

2 The Company's share capital may be increased by the issuance of up to 6'000'000 registered shares to be fully paid up, each with a par value of CHF 0.10 to a nominal value of CHF 600'000.00 by the exercising of conversion or option rights granted to entitled parties in connection with bonds and similar financial instruments or loans of the Company or its subsidiaries that allow for conversion into shares of the Company, or option rights granted to existing and/or new shareholders in connection with capital increases. Subscription rights of shareholders are excluded. The Board of Directors shall determine the conversion and option terms, the issue price and the date of dividend entitlement. The Board of Directors is authorized to limit or exclude the preemptive rights of existing shareholders in the event: (1) of the financing or refinancing of the acquisition of enterprises, parts of enterprises, participations or investments, (2) of the financing or refinancing of the Company or its subsidiaries, (3) of the issuance of convertibles and/or option bonds for the purpose of placement on national or international capital markets (including private placements), (4) for purposes of the underwriting of such bonds and other financial instruments by one or more banks with subsequent public offer; or if the issuance occurs in national or international capital markets, or (5) through a private placement. If the preemptive rights of existing shareholders are excluded and not even granted indirectly, (i) convertibles or option bonds are to be issued on market terms and (ii) the time limit for the exercising of conversion and/or option rights must be set at a maximum of 10 years from the date of the relevant issue. Option rights granted to existing and/or new shareholders in connection with capital increases shall have a time limit for exercising of up to 5 years. The exercise of the option rights and the waiver of such right shall be made in writing on paper or in electronic form.	2 The Company's share capital may be increased by the issuance of up to 35'000'000 registered shares to be fully paid up, each with a par value of CHF 0.10 to a nominal value of CHF 3'500'000.00 by the exercising of conversion or option rights granted to entitled parties in connection with bonds and similar financial instruments or loans of the Company or its subsidiaries that allow for conversion into shares of the Company, or option rights granted to existing and/or new shareholders in connection with capital increases. Subscription rights of shareholders are excluded. The Board of Directors shall determine the conversion and option terms, the issue price and the date of dividend entitlement. The Board of Directors is authorized to limit or exclude the preemptive rights of existing shareholders in the event: (1) of the financing or refinancing of the acquisition of enterprises, parts of enterprises, participations or investments, (2) of the financing or refinancing of the Company or its subsidiaries, (3) of the issuance of convertibles and/or option bonds for the purpose of placement on national or international capital markets (including private placements), (4) for purposes of the underwriting of such bonds and other financial instruments by one or more banks with subsequent public offer; or if the issuance occurs in national or international capital markets, or (5) through a private placement. If the preemptive rights of existing shareholders are excluded and not even granted indirectly, (i) convertibles or option bonds are to be issued on market terms and (ii) the time limit for the exercising of conversion and/or option rights must be set at a maximum of 10 years from the date of the relevant issue. Option rights granted to existing and/or new shareholders in connection with capital increases shall have a time limit for exercising of up to 5 years. The exercise of the option rights and the waiver of such right shall be made in writing on paper or in electronic form.
[new]	Article 33a Contributions in kind (NeuroX)
	[Disclosure of contributions in kind pursuant to Art. 634 para. 4 of the Swiss Code of Obligations]